Harrow (HROW, Financial) has announced that its Vevye Access for All initiative will now cater to patients currently using Klarity-C Drops, a compound cyclosporine product offered by ImprimisRx, Harrow’s compounding arm. Originally launched on March 17, the Vevye Access for All program aims to streamline dry eye treatment for eligible patients by removing common hurdles like prior authorization and reimbursement wait times. The program also features complimentary home delivery and a no-questions-asked, money-back guarantee.
The initiative is designed with flexibility in mind, allowing patients to choose between utilizing their insurance benefits or opting for an affordable cash payment. With this expansion, over 25,000 patients throughout the United States will now have the option to switch their Klarity-C prescriptions to Vevye 0.1%, an FDA-approved remedy for dry eye symptoms, at a cost of $59 per bottle.
Additionally, Klarity-C prescribers have been provided with a prescription authorization platform to facilitate the transfer of prescriptions to PhilRx, making the transition process more efficient.
